EcoDrugPlus

Dihydropyrimidine Dehydrogenase B

Ensembl ID : ENSNFUG00015023011
Gene Symbol: DPYDB
1 Cross references
211 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSNFUG00015010211
Gene Symbol: DDR2
1 Cross references
190 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSNFUG00015009566
Gene Symbol: DDR2
3 Cross references
204 Possible Orthologues:

Disintegrin And Metalloproteinase Domain-Containing Protein 17-Like

Ensembl ID : ENSNFUG00015003637
Gene Symbol: LOC107377926
3 Cross references
210 Possible Orthologues:

Dopamine Receptor D1

Ensembl ID : ENSNFUG00015020009
Gene Symbol: DRD1
3 Cross references
188 Possible Orthologues:

Dopamine Receptor D2a

Ensembl ID : ENSNFUG00015014497
Gene Symbol: DRD2A
1 Cross references
203 Possible Orthologues:

Dopamine Receptor D3

Ensembl ID : ENSNFUG00015021875
Gene Symbol: DRD3
3 Cross references
203 Possible Orthologues:

Dopamine Receptor D4a

Ensembl ID : ENSNFUG00015020319
Gene Symbol: DRD4A
1 Cross references
165 Possible Orthologues:

Dopamine Receptor D4b

Ensembl ID : ENSNFUG00015010122
Gene Symbol: DRD4B
1 Cross references
181 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase Family Member 2-Like

Ensembl ID : ENSNFUG00015021886
Gene Symbol: LOC107394418
3 Cross references
226 Possible Orthologues:

Egl Nine Homolog 2-Like

Ensembl ID : ENSNFUG00015010796
Gene Symbol: LOC107380304
3 Cross references
191 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSNFUG00015010476
Gene Symbol: EGLN1
3 Cross references
220 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).